A new CDC study called the TDF2 study, along with a separate trial released today, provide the first evidence that a daily oral dose of antiretroviral drugs used to treat HIV infection can reduce HIV acquisition among uninfected individuals exposed to the virus through heterosexual sex.

Link:
PrEP Update: CDC Trial and Another Major Study Find PrEP Can Reduce Risk of HIV Infection among Heterosexuals